PMID: 9181649Jan 1, 1997Paper

Loracarbef versus phenoxymethylpenicillin in the treatment of recurrent streptococcal pharyngotonsillitis

Scandinavian Journal of Infectious Diseases
K Roos, P Larsson

Abstract

Knowledge of the treatment of recurrent group A streptococcal pharyngotonsillitis has, so far, been based on studies of non-recurrent rather than recurrent episodes of the disease. This multicentre, double-blind, randomized trial was designed to compare the efficacy of loracarbef (200 mg twice daily) vs phenoxymethylpenicillin (penicillin V) (800/1000 mg twice daily) each for 10 days in the treatment of recurrent group A streptococcal pharyngotonsillitis. Among the 331 patients enrolled in the study, 265 were evaluable for efficacy. The combined clinical and bacteriological failure rate was 8.2% in the loracarbef group and 21.5% in the penicillin V group (p = 0.008). Bacterial eradication was noted in 90% of loracarbef-treated patients compared to 66% of penicillin V-treated patients (p < 0.0005). The higher bacteriological eradication and clinical efficacy rate among loracarbef patients might be related to higher stability of loracarbef in the presence of beta-lactamases produced by the oral microflora. These results suggest loracarbef to be a strong candidate for treatment of patients with recurrent group A streptococcal pharyngotonsillitis.

References

Aug 21, 1992·Science·H C Neu
Aug 1, 1992·The Pediatric Infectious Disease Journal·F A DisneyS A Hausinger
Jan 1, 1991·Scandinavian Journal of Infectious Diseases·C E NordS A Eckernäs
Jan 1, 1987·Scandinavian Journal of Infectious Diseases·E GrahnK Roos
Jan 1, 1994·Scandinavian Journal of Infectious Diseases·A OrrlingC Kamme

❮ Previous
Next ❯

Citations

Jun 13, 2006·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M Pichichero, J Casey
Sep 23, 2000·The Pediatric Infectious Disease Journal·M E PichicheroW Hoeger
Sep 14, 2012·Evidence-based Complementary and Alternative Medicine : ECAM·Surasak LimsuwanSupayang Piyawan Voravuthikunchai
Jul 14, 2005·Scandinavian Journal of Infectious Diseases·Arne OrrlingAnna Stjernquist-Desatnik
Sep 12, 2016·The Cochrane Database of Systematic Reviews·Mieke L van DrielThierry Christiaens
Oct 30, 2004·Scandinavian Journal of Infectious Diseases·Yaseen S SammanMuntasir M Abdelaziz
Apr 14, 2018·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Holger MunckTejs Ehlers Klug
Mar 18, 2021·The Cochrane Database of Systematic Reviews·Mieke L van DrielThierry Christiaens

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved